Human Reproduction, Vol. 18, No. 8, 1632-1636,
August 2003
© 2003 European Society of Human Reproduction and Embryology
Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes
1 Department of Obstetrics and Gynecology and 2 Department of Pediatrics, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
3 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, Shin-Kong Wu Ho-Su Memorial Hospital, No. 95, Wen Chang Road, Shih Lin District, Taipei, Taiwan. e-mail: m002179{at}ms.skh.org.tw
BACKGROUND: The purpose of this study was to determine if there is any additional benefit from FSH priming in addition to hCG priming on in-vitro maturation (IVM) programmes. METHODS: Sixty women with polycystic ovary syndrome (PCOS) who underwent 68 IVM cycles were randomized by computer-generated numbers to receive FSH stimulation or not. Thirty-five cycles were pretreated with 75 IU rFSH for 6 days, and 33 cycles were not. Every cycle was given hCG 10 000 IU 36 h before oocyte retrieval. Immature oocytes were matured in vitro and fertilized by ICSI, and the resulting embryos were replaced on day 2 or 3. RESULTS: A total of 1528 immature oocytes were recovered. The overall maturation and fertilization rates were 74.2 and 72.8% respectively. After embryo transfer, 23 pregnancies resulted (33.8%). The oocyte numbers and endometrial thickness were similar between FSH-primed and non-FSH-primed groups. Serum estradiol level on the day of hCG injection was significantly higher in the FSH-primed group than in the non-FSH-primed group (377.2 pmol/l versus 143.8 pmol/l, P = 0.001). The maturation rate, fertilization rate and pregnancy rate were 76.5, 75.8 and 31.4% respectively for FSH-primed group, and 71.9, 69.5 and 36.4% respectively for non-FSH-primed group (all not significant). CONCLUSIONS: IVM is a feasible treatment for women with PCOS. FSH priming has no additional beneficial effect on IVM.
Key words: ICSI/in-vitro maturation/PCOS/randomized controlled trials
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W.-Y. Son, J.-T. Chung, R.-C. Chian, B. Herrero, E. Demirtas, S. Elizur, Y. Gidoni, C. Sylvestre, N. Dean, and S. L. Tan A 38 h interval between hCG priming and oocyte retrieval increases in vivo and in vitro oocyte maturation rate in programmed IVM cycles Hum. Reprod., September 1, 2008; 23(9): 2010 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Soderstrom-Anttila, T. Salokorpi, M. Pihlaja, S. Serenius-Sirve, and A.-M. Suikkari Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes Hum. Reprod., June 1, 2006; 21(6): 1508 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nogueira, R. Ron-El, S. Friedler, M. Schachter, A. Raziel, R. Cortvrindt, and J. Smitz Meiotic Arrest In Vitro by Phosphodiesterase 3-Inhibitor Enhances Maturation Capacity of Human Oocytes and Allows Subsequent Embryonic Development Biol Reprod, January 1, 2006; 74(1): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Soderstrom-Anttila, S. Makinen, T. Tuuri, and A.-M. Suikkari Favourable pregnancy results with insemination of in vitro matured oocytes from unstimulated patients Hum. Reprod., June 1, 2005; 20(6): 1534 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Le Du, I.J. Kadoch, N. Bourcigaux, S. Doumerc, M-C. Bourrier, N. Chevalier, R. Fanchin, R-C. Chian, G. Tachdjian, R. Frydman, et al. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience Hum. Reprod., February 1, 2005; 20(2): 420 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takeuchi, Z. Rosenwaks, and G. D. Palermo A successful model to assess embryo development after transplantation of prophase nuclei Hum. Reprod., April 1, 2004; 19(4): 975 - 981. [Abstract] [Full Text] [PDF]
|
|